- Global Pharma News & Resources

Stem Cell Therapies in Neurology, 2018 -

The "Stem Cell Therapies in Neurology, 2018" report has been added to's offering.

"Stem Cell Therapies in Neurology", is an evolving field. The current pipeline of products feature different types of stem cells and these therapies have the potential to target a range of neurological diseases. However, there are challenges associated with the development of these therapies, including the need to demonstrate strong safety and efficacy data.

Biotechnology companies currently dominate in this field and are expected to lead the development of different pipeline products.

The current pipeline consists of 16 products (Phase 1,2, and 3), and the most common indications for which these products are being evaluated include Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Parkinson's Disease. The most commonly understood mechanism of action underlying stem cells therapy in neurology is the potential ability of these therapies to secrete trophic factors that help in neuronal survival and growth.

As research in this field progresses, it is expected to help further improve the understanding of how these therapies work and, potentially address unmet needs in the field of neurology.

Companies Featured
  • Asterias Biotherapeutics Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Neuralstem Inc.
  • SanBio Inc.
  • Shanghai Angecon Biotechnology Corp.
  • Stemedica Cell Technologies Inc.

Key Topics Covered

1. Introduction

2. Executive Summary

2.1 Key Findings

2.2 KOL Insights on Stem Cell Therapy Competitive Landscape

3. Overview of Stem Cells for Neurology and Epidemiology

3.1 Regenerative Medicine

3.2 Common Types of Stem Cells Employed in Current Pipeline Products

3.3 Stem Cells for Neurology

3.4 Factors to Be Considered When Deciding Stem Cell Strategy

3.5 Epidemiology of Neurology Indications

4. Regulatory Oversight of Stem Cell Therapies

4.1 Regulatory Agencies in the US and EU

4.2 The FDA and Regenerative Medicine

4.3 Regulatory Agencies in Japan

4.4 Regulatory Agencies in China

5. Pipeline Assessment, Profiled Stem Cell Therapies

5.1 Pipeline Overview for Neurology

5.2 Neurology Stem Cell Therapy Development

5.3 Pipeline Stem Cell Therapies Targeting Neurology Diseases

5.4 Pipeline Product: NurOwn

5.5 Pipeline Product: ANGES-003

5.6 Pipeline Product: NSI-566

5.7 Some Early-Stage Therapies with Limited Clinical Data

6. Clinical Trials and Key Developers

6.1 Overview of Clinical Trials

6.2 Clinical Trial Mapping

6.3 Challenges of Conducting Stem Cell Clinical Trials in Neurology

6.4 Key Players

7. Market Access: Reimbursement, Pricing, Unmet Need

7.1 Market Access

7.2 Stem Cell Therapy Reimbursement

7.3 Unmet Need Within Neurology

7.4 Stem Cell Therapy Reimbursement for Some Profiled Pipeline Products

8. Market Outlook

8.1 Market Outlook for BrainStorm Therapeutics' NurOwn

8.2 Market Outlook for Shanghai Angecon's ANGES-003

8.3 Market Outlook for Neuralstem's NSI-566

8.4 Anticipated Key Events for Stem Cell Therapies in Neurology

For more information about this report visit

View source version on

Editor Details

Last Updated: 03-Dec-2018